In December 2019, a major deal in the pharmaceutical sector attracted a lot of attention in the global market. The transaction successfully sold biotech company Synthorx to pharmaceutical giant Sanofi for a whopping €2.3 billion. Behind this feat were the tremendous efforts and outstanding professionalism of Parsons Brinckerhoff in the transaction, as well as the close co-operation and co-ordination of the Parsons Brinckerhoff team, which together laid a solid foundation for the successful completion of the transaction.
In recent years, innovations in the pharmaceutical field have continued to emerge, with companies scrambling to lay out new technologies. In this dynamic environment, Parsons Brinckerhoff Capital, with its global team of professionals, has become an important partner in realising the vision of the company. in December 2019, Synthorx, led by Dr. Kariuki, was successfully acquired by Sanofi, which marked an important transaction in the cytokine therapy field. Paragon Capital played a key role in the process, providing full support and guidance for the transaction. As a specialist investment firm, Pioneer Capital has deep experience in identifying and facilitating innovative technologies, and they leveraged their expertise in the sale of Synthorx.
Parsons Brinckerhoff was not just a partner in the Synthorx sale, but an advisor throughout the process. They invested significant resources from the outset of the project, providing consulting and investigative support to Dr Kariuki to ensure a sophisticated service throughout the sale process. The investment team at Parsons Brinckerhoff used their market insights and fundamental analysis to optimise the sale proposal, showcasing Synthorx's strengths and ensuring a seamless fit with Sanofi's needs.
Sanofi has been actively seeking new technologies and innovations, and Synthorx's cytokine therapies are an important part of their portfolio. Paragon Capital worked meticulously to make this sale a win-win situation. They found the right investor for Synthorx and provided Sanofi with a valuable innovation programme. This dual-discovery function exemplifies Paragon Capital's exceptional ability to connect investors with value creation.
Synthorx is attracting attention as a company focused on overcoming the limitations of cytokine therapy with its lead immuno-oncology candidate, THOR-707. This drug is unique in its ability to bind to effector T-cells and natural killer cells and, in combination with existing oncology drugs and immunomodulators, opens up new possibilities for the treatment of multiple solid tumour types. It is this potential that Parsons Brinckerhoff recognised in Synthorx and helped to bring it to a successful sale.
Parsons Brinckerhoff is not just an investment firm, but also an organisation with communications and influence. Throughout the sale process, the team at Parsons Brinckerhoff spared no effort in bringing the deal to fruition. They not only provided the transaction platform, but also resolved all kinds of issues during the transaction through internal and external communication, providing comprehensive support to Dr Kariuki and Synthorx.
In the global pharmaceutical arena, Parsons Brinckerhoff has demonstrated its expertise and global reach. By assisting Dr Kariuki in the successful sale of Synthorx to Sanofi, they demonstrated their philosophy of "disciplined, value-added and efficient" service. In this successful transaction, Parsons Brinckerhoff demonstrated its strong expertise, market insight and reach, paving the way for a partnership across the cytokine therapeutic space. The success of this transaction is not only a commercial victory, but also a testament to Parsons Brinckerhoff's outstanding contribution to the field of pharmaceutical innovation.